EPILEPSY THERAPIES & DIAGNOSTICS DEVELOPMENT XVIII

(ETDD - formally AEDD)

May 28st – 30th, 2025
Lansdowne Resort
44050 Woodridge Parkway
Leesburg, Virginia 20176

 
AED XIV group photo.JPG

Welcome to the website for the 18th conference on Epilepsy Therapies & Diagnostic Development (formally the Antiepileptic Drug & Device Symposium), held every two years and sponsored by the Epilepsy Study Consortium, Inc. in collaboration with the University of Pennsylvania and the Epilepsy Foundation.

If you have any questions about the conference, please contact Tracy DeVito [devito@epilepsyconsortium.org] or Bree DiVentura [diventura@epilepsyconsortium.org] at the Epilepsy Study Consortium.

Program

This is the eighteenth conference focusing on issues related to Epilepsy Therapies & Diagnostic Developments (ETDD) from preclinical discoveries through clinical evaluations. We are fortunate to have a robust epilepsy drug and device pipeline, fueled by excellent science and novel ideas.  We are entering an exciting era where therapies targeted at disease modification , rather than just anti-seizure treatment are emerging, and there is a focus on personalized treatments. There are also many treatments in the pipeline for orphan diseases. There is a burgeoning pipeline of wearable and implantable diagnostic devices. New therapeutic devices are also under development. New innovations in therapy and diagnostics  may face roadblocks such as complex regulatory requirements, increased payer expectations, and issues in data quality, but progress has been made. At each ETDD conference, we re-evaluate strategies to ensure continued advancement. There is always the opportunity to learn from the past as we move into the future. This symposium will bring together representatives from academia, industry, and the NIH, to review what has been learned and to discuss strategies to enhance epilepsy therapy and diagnostics development.

Click HERE (or on the program image) to download the program from 2023.

The program for 2025 will be available early in 2025.

 

Registration - Conference & Hotel

conference registration & Payment

Mark your calendars and SAVE THE DATE for the ETDD XVIII Meeting May 28th-30th, 2025!

 

Hotel reservations

We are planning an in-person meeting in a new venue :

Lansdowne Resort
44050 Woodridge Parkway, Leesburg, Virginia 20176

REGISTRATION FOR THE 2025 MEETING IS DUE TO OPEN IN LATE FEBRUARY.

 

Meeting Purpose

 

In an era where we have BROUGHT numerous new antiepileptic drugs to the marketplace, we need to be mindful of the unmet needs….

For more than three decades a group of individuals have been meeting on a biennial basis to discuss ways in which the process of bringing innovative therapies and devices to patients can be expedited. Participants include individuals from academia, from interested government agencies, as well as representatives from the pharmaceutical and device industries. The purpose of these meetings has been the exchange of ideas, discussion of roadblocks to therapeutic and diagnostic development, dialogue about regulatory strategies, and sharing of successful approaches. Over the years, discussions at this symposium have led to implementation of new trial designs, as well as new important analyses of trials that have already been performed. In addition, new regulatory pathways have been identified, particularly as related to approval of new antiepileptic drugs for monotherapy use. In addition, each meeting presents a pipeline of drugs and devices currently in development, and includes a Shark Tank competition, where novel innovations to improve the lives of people with epilepsy are presented.

 
 

Objectives

word cloud 1.png

During the course of the meeting, participants will:

  • Obtain an understanding of the processes by which new drugs are discovered, including discussion of new animal models and molecular targets.

  • Discuss new translational models in the epilepsy space.

  • Discuss new regulatory pathways for epilepsy approval, including orphan indications.

  • Discuss new ways to assess seizure frequency in trials, including electronic seizure diaries, wearable devices, and continuous EEG.

  • Discuss new objectives and legislation that have an impact on ASM development.

  • Discuss novel outcome measures, including those for co-morbidities.

  • Summarize discussions from previous Research Roundtables for Epilepsy regarding measurement of seizure impact beyond seizure counts.

  • Outline the drugs and devices in preclinical and clinical development for epilepsy.